Non-Small Cell Lung Cancer (NSCLC): Targeted Therapy and Immunotherapy Guide — Overview, Diagnosis & Treatment Options | MyMedicPlus

Non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers and includes three major histological subtypes: adenocarcinoma (40%), squamous cell carcinoma (25-30%), and large cell carcinoma (10%). Approximately 200,000 new US cases are diagnosed annually. The majority (approximately 57%) present at advanced (Stage IV) disease. Survival has improved substantially with driver mutation-targeted therapies and checkpoint immunotherapy over the past decade. Non-Small Cell Lung Cancer (NSCLC): Targeted Therapy and Immunotherapy Guide is a medical condition that affects patients across various age groups and demographics. It requires proper medical attention and management. This page provides evidence-based information about Non-Small Cell Lung Cancer (NSCLC): Targeted Therapy and Immunotherapy Guide to help patients understand the condition, its causes, symptoms, and available treatment options.

Cigarette smoking is the dominant risk factor, causing approximately 85% of NSCLC cases. Radon gas is the second leading cause (estimated 21,000 US deaths per year). Occupational carcinogens including asbestos, arsenic, chromium, nickel compounds, and polycyclic aromatic hydrocarbons confer additional risk. Air pollution (PM2.5) correlates with NSCLC incidence. Second-hand smoke increases never-smoker risk. Never-smokers developing adenocarcinoma frequently harbor driver mutations: EGFR (10-15% overall, 50% in Asian females), ALK, ROS1, RET, NTRK, and MET exon 14 alterations. The causes of Non-Small Cell Lung Cancer (NSCLC): Targeted Therapy and Immunotherapy Guide are often multifactorial, involving a combination of genetic predisposition, environmental exposures, and lifestyle factors. In some cases, infectious agents, immune dysfunction, or metabolic imbalances may contribute. Risk factors vary but may include age, sex, family history, and pre-existing medical conditions. Understanding the causes guides prevention strategies and informs treatment choices.

Persistent or worsening cough, hemoptysis, dyspnea, and chest pain are common presentations. Hoarseness from recurrent laryngeal nerve compression, Horner syndrome (apical Pancoast tumor invading cervical sympathetics), and superior vena cava syndrome (mediastinal involvement) indicate locally advanced disease. Paraneoplastic syndromes include SIADH (adenocarcinoma), hypercalcemia from PTHrP secretion (squamous), Eaton-Lambert myasthenic syndrome (uncommonly NSCLC), and hypertrophic pulmonary osteoarthropathy. Many early-stage NSCLC cases are asymptomatic and detected on LDCT screening. Symptoms of Non-Small Cell Lung Cancer (NSCLC): Targeted Therapy and Immunotherapy Guide can range from mild to severe and may develop gradually or appear suddenly. Common presentations include pain, inflammation, or functional impairment related to the affected system. Symptoms may fluctuate over time with periods of remission and exacerbation. Consult a healthcare provider if symptoms persist or worsen, as early diagnosis improves outcomes.

Annual LDCT screening is recommended for high-risk adults (50-80 years, greater than or equal to 20 pack-year history, current or former smoker within 15 years). Tissue diagnosis is obtained by bronchoscopy with EBUS-TBNA for central lesions or CT-guided needle biopsy for peripheral tumors. Comprehensive molecular profiling by NGS (EGFR, ALK, ROS1, KRAS G12C, BRAF V600E, MET exon 14, RET, NTRK, HER2) and PD-L1 TPS by immunohistochemistry guides first-line therapy selection. PET-CT and brain MRI complete systemic staging per AJCC 8th edition TNM. Diagnosis of Non-Small Cell Lung Cancer (NSCLC): Targeted Therapy and Immunotherapy Guide typically involves a thorough clinical history, physical examination, and targeted investigations. Laboratory tests, imaging studies, or specialist referrals may be required to confirm the diagnosis. Accurate diagnosis is essential for appropriate management and prevents unnecessary treatment.

Stage I-II: anatomical resection (lobectomy via VATS preferred); adjuvant osimertinib for 3 years in Stage IB-IIIA EGFR-mutant (ADAURA); adjuvant atezolizumab for PD-L1-positive Stage II-IIIA (IMpower010). Stage III unresectable: concurrent platinum-doublet chemotherapy plus 60-66Gy radiation followed by 12 months durvalumab consolidation (PACIFIC). Stage IV with driver mutation: osimertinib (EGFR), alectinib or brigatinib (ALK), crizotinib or entrectinib (ROS1 or NTRK), sotorasib or adagrasib (KRAS G12C), tepotinib (MET ex14). No driver mutation with PD-L1 greater than or equal to 50%: pembrolizumab monotherapy. Others: pembrolizumab plus platinum doublet. Treatment of Non-Small Cell Lung Cancer (NSCLC): Targeted Therapy and Immunotherapy Guide is tailored to the individual and depends on severity and underlying cause. Options may include medications, lifestyle modifications, surgical interventions, or supportive therapies. Multidisciplinary care is often recommended for complex cases. The goal is to alleviate symptoms, slow disease progression, and improve quality of life.

Five-year OS by pathological stage: Stage IA1 92%, Stage IA2 83%, Stage IA3 77%, Stage IB 68%, Stage IIA 60%, Stage IIB 53%, Stage IIIA 36%, Stage IIIB 26%, Stage IV 10% overall. Osimertinib for EGFR-mutant metastatic NSCLC: median OS 38.6 months (FLAURA). Alectinib for ALK-rearranged: 5-year OS approximately 62% (ALEX trial). Pembrolizumab for PD-L1 greater than or equal to 50%: 5-year OS approximately 31% (KEYNOTE-024). LDCT screening reduces lung cancer mortality by 20% (NLST) to 26% (NELSON). The prognosis for Non-Small Cell Lung Cancer (NSCLC): Targeted Therapy and Immunotherapy Guide varies depending on severity at diagnosis, the patient's overall health, and how promptly treatment is initiated. With early diagnosis and appropriate management, many patients achieve good outcomes and maintain quality of life. Regular follow-up with healthcare providers is essential to monitor progress, adjust treatment as needed, and detect any complications early. Adherence to prescribed treatments and lifestyle modifications significantly improves long-term prognosis.

Smoking cessation is the most effective prevention: risk decreases progressively after quitting and approaches near-baseline after 10-15 years. Radon testing with mitigation if greater than 4 pCi/L is highly effective secondary prevention. Occupational carcinogen controls (asbestos abatement, engineering controls for chromium and arsenic compounds) reduce workplace exposure. Annual LDCT for high-risk individuals (50-80 years, greater than or equal to 20 pack-year history) reduces lung cancer mortality by 20-26%. Avoidance of second-hand smoke environments. Indoor air quality improvement (cooking fume reduction) protects never-smoking women in high-incidence Asian populations.

Go to the ER immediately for acute respiratory failure, superior vena cava syndrome (progressive facial and arm swelling, dilated neck veins, headache — a thoracic emergency), large-volume haemoptysis, or a new acute neurological deficit from a brain metastasis. See a pulmonologist or oncologist urgently for persistent or worsening cough lasting more than 3 weeks in a smoker; any amount of haemoptysis; progressive unexplained dyspnea with weight loss; new hoarseness without laryngitis in a smoker; or a suspicious lung nodule requiring Lung-RADS follow-up on any imaging. Routine early detection: annual low-dose CT is recommended for all high-risk adults aged 50-80 with a 20 or more pack-year smoking history who currently smoke or who quit within the past 15 years.